No products in the cart.
CSF2RA: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It’s the GeneMedi’s summary page for Target/Biomarker Introduction of CSF2RA. The page also collects GeneMedi’s different modalities and formats products for CSF2RA in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the CSF2RA target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is the alpha subunit of the heterodimeric receptor for colony stimulating factor 2, a cytokine which controls the production, differentiation, and function of granulocytes and macrophages. The encoded protein is a member of the cytokine family of receptors. This gene is found in the pseudoautosomal region (PAR) of the X and Y chromosomes. Multiple transcript variants encoding different isoforms have been found for this gene, with some of the isoforms being membrane-bound and others being soluble. [provided by RefSeq, Jul 2008]
|
Target ID |
GM-T73097
|
|
Target Name |
CSF2RA
|
|
Gene ID |
1438
|
|
Gene Official Name |
CSF2RA
|
|
Gene Alias |
CD116, CDw116, CSF2RX, CSF2RAY, CSF2RX, CSF2RY, GM-CSF-R-alpha, GMCSFR, GMR, SMDP4, alphaGMR, CSF2RA
|
|
Protein Sub-location |
Transmembrane Protein
|
|
Category |
Therapeutics Target, Immuno-oncology Target, INN Index
|
Pre-made CSF2RA-specific INN-index biosimilar (antibody&conjugates)-sargramostim, Mavrilimumab
Anti-CSF2RA therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Filters
Sort results
Reset
Apply
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Order |
|---|---|---|---|---|---|---|
Pre-Made Mavrilimumab biosimilar, Whole mAb, Anti-CSF2RA Antibody: Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha therapeutic antibody |
Mavrilimumab |
favezelimab |
CSF2RA |
Whole mAb |
||
Pre-Made Sargramostim Biosimilar, Recombinant Protein targeting CSF2RA: Recombinant therapeutic protein targeting CD116/CDw116/CSF2R/CSF2RAX/CSF2RAY/CSF2RX/CSF2RY/GM-CSF-R-alpha/GMCSFR/GMCSFR-alpha/G |
sargramostim |
NA |
CSF2RA |
Recombinant Protein |
Anti-CSF2R/ CSF2RA/ CD116 antibody for FACS & in-vivo assay| GMab
Pre-made anti-CSF2RA benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CSF2RA mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Filters
Sort results
Reset
Apply
Cat No. | Antibody Name | Format | Classified by tag | Order
|
|---|---|---|---|---|
Anti-CSF2RA monoclonal antibody |
mab |
FACS/Biofunctional Antibody, Therapeutics Target antibody |
